Mode
Text Size
Log in / Sign up

Clinicoradiomics models provide superior and more consistent performance for predicting microvascular invasion in hepatocellular carcinomaRadiomics Models Help Predict Microvascular Invasion in Liver Cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that clinicoradiomics models provide superior and more consistent performance for predicting MVI in HCC.

This meta-analysis synthesized data from 26 studies to evaluate the diagnostic performance of radiomics-based models, including CT-based, MRI-based, and clinicoradiomics models, for predicting microvascular invasion (MVI) in patients with hepatocellular carcinoma. The analysis focused on Area Under the Curve (AUC) as the primary metric for diagnostic performance.

The synthesis indicates that radiomics models generally demonstrate good diagnostic performance with an AUC of 0.85 (95% CI 0.82-0.88). Specifically, clinicoradiomics models showed higher and more consistent performance compared to radiomics-only models in both imaging modalities. For MRI, clinicoradiomics models achieved an AUC of 0.87 compared to 0.85 for radiomics-only models. For CT, clinicoradiomics models achieved an AUC of 0.87 compared to 0.81 for radiomics-only models.

Several limitations were noted, including considerable heterogeneity among the included studies and limited external validation. While these models show promise for preoperative prediction of MVI, clinical implementation requires further methodological standardization and prospective multicenter validation to establish definitive utility.

How this fits prior evidence

This meta-analysis addresses a gap in non-invasive diagnostic tools for hepatocellular carcinoma. While previous coverage identified exosomal miRNAs as promising but unvalidated biomarkers and noted the role of RPN1 in immune evasion, this study focuses on the diagnostic performance of radiomics-based models. It specifically highlights that incorporating clinical variables into radiomics models improves the prediction of microvascular invasion compared to radiomics-only models.

Researchers analyzed 26 studies to see how well radiomics models could predict microvascular invasion (MVI) in patients with hepatocellular carcinoma (HCC). Radiomics are data points extracted from medical images like CT and MRI scans. The study found that these models showed good diagnostic performance for predicting MVI.

Specifically, the results showed that clinicoradiomics models—which combine image data with clinical information—performed better and more consistently than radiomics-only models. This was observed in both CT and MRI scans. These models are currently used to help doctors understand the extent of liver cancer before surgery.

Because the study involved many different types of research, there was a lot of variation in the data. There was also limited testing in different hospital settings. While these tools show promise for predicting cancer spread, more standardized testing across many centers is needed before they can be used routinely in every clinic.

What this means for you:
Clinicoradiomics models show promising results for predicting microvascular invasion in liver cancer patients.

Common questions

What are radiomics models and how do they help?

Radiomics models are tools that extract data from medical images like CT and MRI scans. In this study, they were used to predict microvascular invasion in patients with liver cancer. The results showed that these models had good diagnostic performance, with an area under the curve of 0.85.

Is it better to use radiomics alone or combined with clinical data?

The study found that clinicoradiomics models, which combine image data with clinical information, performed better and more consistently than radiomics-only models. This was true for both CT and MRI scans, showing higher performance scores of 0.87 compared to lower scores for radiomics alone.

Can these models be used in every hospital right now?

While the results are promising, the study notes that these models are not yet ready for universal use. Because the data was varied and lacked large-scale testing in different locations, more standardized and multi-center testing is needed before they can be used routinely in clinical practice.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
This systematic review and meta-analysis evaluated the diagnostic performance of radiomics-based models for predicting microvascular invasion (MVI) in hepatocellular carcinoma (HCC). MVI is a key determinant of prognosis in HCC, strongly associated with early recurrence and reduced survival following curative treatment. Accurate preoperative prediction of MVI remains challenging using conventional clinical and imaging features. Radiomics has emerged as a promising approach by enabling quantitative analysis of tumor heterogeneity from medical imaging. This study aimed to systematically evaluate the diagnostic performance of radiomics-based models for predicting MVI in HCC. A systematic review and meta-analysis were conducted, including 26 studies evaluating CT- and MRI-based radiomics models. Data on diagnostic performance were extracted, and pooled analyses were performed using random-effects models, with subgroup analyses by imaging modality and model type. Overall, radiomics models demonstrated good diagnostic performance, with a pooled AUC of 0.85 (95% CI 0.82-0.88). Clinicoradiomics models achieved higher and more consistent performance than radiomics-only models (MRI: 0.87 vs 0.85; CT: 0.87 vs 0.81). Among 3D-based models, the pooled AUC was 0.85 (95% CI 0.82-0.88). In conclusion, radiomics-based models show promising performance for preoperative prediction of MVI in HCC, particularly when combined with clinical variables. However, considerable heterogeneity and limited external validation highlight the need for methodological standardization and prospective multicenter validation before clinical implementation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.